Ziprosidone-Induced Transient Agranulocytosis;Delayed Onset of Cardiac Adverse Effects with Fingolimod;Telmisartan-Induced Myotoxicity;Severe Dilated Cardiomyopathy Induced by Adalimumab and Ustekinumab
Restricted accessResearch articleFirst published online November, 2015
Ziprosidone-Induced Transient Agranulocytosis;Delayed Onset of Cardiac Adverse Effects with Fingolimod;Telmisartan-Induced Myotoxicity;Severe Dilated Cardiomyopathy Induced by Adalimumab and Ustekinumab
The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), discuss methods of prevention, and promote reporting of ADRs to the US Food and Drug Administration's (FDA's) MedWatch program (800-FDA-1088). If you have reported an interesting, preventable ADR to MedWatch, please consider sharing the account with our readers.
Get full access to this article
View all access options for this article.
References
1.
IskandarJW, VanceJE, Kablinger, Transient agranulocytosis associated with ziprasidone in a 45-year-old man on hemodialysis. J Clin Psychopharmacol.2015;35(3):347–348.
2.
RosiniJM, RajasimhanS, FellowsSE, Delayed cardiac dysrhythmias after fingolimod administration. Am J Emerg Med.2015;33:987.e1–987.e3.
3.
BarvaliyaMJ, NaikVN, ShahAC, Safety of olmesartan in a patient with telmisartan-induced myotoxicity: A case report. Br J Clin Pharmacol.2015;79(6):1034–1036.
4.
Membrillo de NovalesFJ, JimenezAA, MelendezLM, Severe dilated cardiomyopathy induced by adalimumab and ustekinumab. J Clin Rheumatol.2015;21(3):170–172.
